Intrinsic Value of S&P & Nasdaq Contact Us

CEL-SCI Corporation CVM NYSE

NYSE • Healthcare • Biotechnology • US • USD

SharesGrow Score
60/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

CEL-SCI Corporation (CVM) — Analyst outlook / Analyst consensus target is. Based on 6 analyst ratings, the consensus is bullish — 6 Buy.

Analysts estimate Earnings Per Share (EPS) of $-19.80 and revenue of $0.00B for the next fiscal year.

Earnings Per Share (EPS) track record: 2024: actual $-0.51 vs est $-19.80 (beat +97.4%). 2025: actual $-6.27 vs est $-4.51 (missed -39%). Analyst accuracy: 0%.

CVM Analyst Ratings

Buy
6
Ratings
6 Buy
Based on 6 analysts giving stock ratings to CEL-SCI Corporation in the past 3 months
Rating breakdown
Buy
6 100%
100%
Buy
6 analysts
0%
Hold
0 analysts
0%
Sell
0 analysts

EPS Estimates — CVM

0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024 Actual –$0.51 vs Est –$19.80 ▲ 3,782.4% off
2025 Actual –$6.27 vs Est –$4.51 ▼ 28.1% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.

Revenue Estimates — CVM

Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message